Galapagos, Roche enter $588.7M COPD alliance

Galapagos and Roche have entered a global alliance to develop new COPD therapies in a deal worth almost $590 million (€406 million). Galapagos will use its discovery platform to identify potential COPD targets and develop small molecule candidates against the targets. Roche will select the candidates it wants to develop after either clinical candidate selection or completion of Phase I trials. The company will then be fully responsible for further development of the drugs it licenses. Galapagos gets $8.7 million (€6 million) up front and could earn an additional $580 million (€400 million) in milestones.

Read the full article at FierceBiotech